SCHEMBL4594096

SCHEMBL4594096

O=C(O)ON1CCc2ccc([N+](=O)[O-])cc2CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.46
ADRA2A P08913 1/20 0.46
PNMT P11086 1/20 0.46
GRIN2B Q13224 2/20 0.45
HPGD P15428 1/20 0.42
CPT2 P23786 1/20 0.41
CPT1A P50416 1/20 0.41
HSP90AA1 P07900 1/20 0.41
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
KMT2A Q03164 2/20 0.40
SIRT2 Q8IXJ6 1/20 0.40
POLB P06746 1/20 0.40
DRD2 P14416 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2570871 0.82 DRD2 (0.49) AKR1C3ADRA2APNMTGRIN2BALDH1A1
SCHEMBL2062288 0.81 PNMT (0.49) AKR1C3ADRA2APNMTGRIN2BALDH1A1
SCHEMBL17797648 0.81 HPGD (0.51) AKR1C3ADRA2APNMTGRIN2BHPGD
SCHEMBL6097088 0.79 MEN1 (0.53) ADRA2APNMTHPGDALDH1A1SMN1; SMN2
SCHEMBL3467138 0.77 DRD2 (0.48) AKR1C3ADRA2APNMTGRIN2BDRD2
SCHEMBL1950525 0.77 PNMT (0.54) ADRA2APNMTGRIN2BHPGDALDH1A1
SCHEMBL7738183 0.77 DRD2 (0.45) AKR1C3ADRA2APNMTGRIN2BHPGD
SCHEMBL2310023 0.77 ALDH1A1 (0.55) AKR1C3ADRA2APNMTHPGDALDH1A1
SCHEMBL30709850 0.76 PNMT (0.65) ADRA2APNMTGRIN2BALDH1A1MEN1
SCHEMBL9483063 0.76 PNMT (0.65) ADRA2APNMTGRIN2BALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899330-A1 SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT Boehringer Ingelheim International GmbH (DE) 2008-03-19 EP disclosed
WO-2007003536-A1 SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-01-11 WO disclosed